NET silencing by let-7i in postural tachycardia syndrome

Abdul Waheed Khan, Mark Ziemann, Susan J. Corcoran, Harikrishnan K N, Jun Okabe, Haloom Rafehi, Scott S. Maxwell, Murray D. Esler, Assam El-Osta

Research output: Contribution to journalArticleResearchpeer-review

Abstract

While strongly implicated in postural tachycardia syndrome (POTS), considerable controversy exists regarding norepinephrine transporter (NET) loss of function. POTS is characterized by the clinical symptoms of orthostatic intolerance, lightheadedness, tachycardia, and syncope or near syncope with upright posture. Abnormal sympathetic nervous system activity is typical, of a type which suggests dysfunction of the NET, with evidence that the gene responsible is under tight epigenetic control. Using RNA of isolated chromatin combined with massive parallel sequencing (RICh-seq) we show that let-7i miRNA suppresses NET by methyl-CpG-binding protein 2 (MeCP2). Vorinostat restores epigenetic control and NET expression in leukocytes derived from POTS participants.

Original languageEnglish
Article numbere90183
Number of pages11
JournalJCI Insight
Volume2
Issue number6
DOIs
Publication statusPublished - 23 Mar 2017

Cite this

Khan, Abdul Waheed ; Ziemann, Mark ; Corcoran, Susan J. ; K N, Harikrishnan ; Okabe, Jun ; Rafehi, Haloom ; Maxwell, Scott S. ; Esler, Murray D. ; El-Osta, Assam. / NET silencing by let-7i in postural tachycardia syndrome. In: JCI Insight. 2017 ; Vol. 2, No. 6.
@article{3dc3a8f367104323ac7770f8e35a7bc9,
title = "NET silencing by let-7i in postural tachycardia syndrome",
abstract = "While strongly implicated in postural tachycardia syndrome (POTS), considerable controversy exists regarding norepinephrine transporter (NET) loss of function. POTS is characterized by the clinical symptoms of orthostatic intolerance, lightheadedness, tachycardia, and syncope or near syncope with upright posture. Abnormal sympathetic nervous system activity is typical, of a type which suggests dysfunction of the NET, with evidence that the gene responsible is under tight epigenetic control. Using RNA of isolated chromatin combined with massive parallel sequencing (RICh-seq) we show that let-7i miRNA suppresses NET by methyl-CpG-binding protein 2 (MeCP2). Vorinostat restores epigenetic control and NET expression in leukocytes derived from POTS participants.",
author = "Khan, {Abdul Waheed} and Mark Ziemann and Corcoran, {Susan J.} and {K N}, Harikrishnan and Jun Okabe and Haloom Rafehi and Maxwell, {Scott S.} and Esler, {Murray D.} and Assam El-Osta",
year = "2017",
month = "3",
day = "23",
doi = "10.1172/jci.insight.90183",
language = "English",
volume = "2",
journal = "JCI Insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

NET silencing by let-7i in postural tachycardia syndrome. / Khan, Abdul Waheed; Ziemann, Mark; Corcoran, Susan J.; K N, Harikrishnan; Okabe, Jun; Rafehi, Haloom; Maxwell, Scott S.; Esler, Murray D.; El-Osta, Assam.

In: JCI Insight, Vol. 2, No. 6, e90183, 23.03.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - NET silencing by let-7i in postural tachycardia syndrome

AU - Khan, Abdul Waheed

AU - Ziemann, Mark

AU - Corcoran, Susan J.

AU - K N, Harikrishnan

AU - Okabe, Jun

AU - Rafehi, Haloom

AU - Maxwell, Scott S.

AU - Esler, Murray D.

AU - El-Osta, Assam

PY - 2017/3/23

Y1 - 2017/3/23

N2 - While strongly implicated in postural tachycardia syndrome (POTS), considerable controversy exists regarding norepinephrine transporter (NET) loss of function. POTS is characterized by the clinical symptoms of orthostatic intolerance, lightheadedness, tachycardia, and syncope or near syncope with upright posture. Abnormal sympathetic nervous system activity is typical, of a type which suggests dysfunction of the NET, with evidence that the gene responsible is under tight epigenetic control. Using RNA of isolated chromatin combined with massive parallel sequencing (RICh-seq) we show that let-7i miRNA suppresses NET by methyl-CpG-binding protein 2 (MeCP2). Vorinostat restores epigenetic control and NET expression in leukocytes derived from POTS participants.

AB - While strongly implicated in postural tachycardia syndrome (POTS), considerable controversy exists regarding norepinephrine transporter (NET) loss of function. POTS is characterized by the clinical symptoms of orthostatic intolerance, lightheadedness, tachycardia, and syncope or near syncope with upright posture. Abnormal sympathetic nervous system activity is typical, of a type which suggests dysfunction of the NET, with evidence that the gene responsible is under tight epigenetic control. Using RNA of isolated chromatin combined with massive parallel sequencing (RICh-seq) we show that let-7i miRNA suppresses NET by methyl-CpG-binding protein 2 (MeCP2). Vorinostat restores epigenetic control and NET expression in leukocytes derived from POTS participants.

UR - http://www.scopus.com/inward/record.url?scp=85041684549&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.90183

DO - 10.1172/jci.insight.90183

M3 - Article

VL - 2

JO - JCI Insight

JF - JCI Insight

SN - 2379-3708

IS - 6

M1 - e90183

ER -